



Clinical Trials of Texas, Inc.

Dedicated to the advancement of new medical therapies.

Curriculum Vitae

Celyna Donna Delgado, MD

7940 Floyd Curl Drive, Suite 700
San Antonio, Texas 78229

7950 Floyd Curl Drive, Suite 600
San Antonio, Texas 78229

EDUCATION

- 1987-1991 Residency - Obstetrics and Gynecology, Louisiana State University Medical Center, New Orleans, Louisiana
1987 Doctor of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas
1978 Bachelors of Science in Pharmacy, The University of Texas at Austin, Austin, Texas

LICENSURE

- 1991 Florida Medical Board, # ME59525 (inactive)
1989 Louisiana Medical Board, # 07930R (inactive)
1988 Texas Medical Board, # H4278
1979 Pharmacy Licensure in Texas, # 23966 (inactive)

HOSPITAL APPOINTMENTS

Southwest Texas Methodist Hospital
St. Luke's Baptist Hospital

RESEARCH AFFILIATIONS

2006-Present Investigator, Clinical Trials of Texas, Inc., San Antonio, Texas

PROFESSIONAL EXPERIENCE

- 1996-Present Institute for Women's Health, San Antonio, Texas
1994-1996 Live Oak OB/GYN Associates, San Antonio, Texas
1991-1994 Private Practice – Two member group, Obstetrics and Gynecology, Key West, Florida
1979-1983 Pharmacist, University of Texas Medical Branch, Galveston, Texas

RESEARCH EXPERIENCE

2008-Present: A Multi-Center, Randomized, Controlled Study To Investigate The Safety And Tolerability Of A Single Dose Of "Study Drug" vs. Standard Medical Care In Treating Iron Deficiency Anemia In Subjects Who Are Not Dialysis Dependent

2008-Present: A Multicenter, Randomized, Controlled Study To Investigate The Safety And Tolerability Of "Study Drug" vs. Standard Medical Care In Treating Iron Deficiency Anemia

2008-Present: A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Uterine Fibroids

2008-Present: Efficacy And Safety Of "Study Drug" In The Treatment Of Moderate To Severe Vaginal Dryness And Vaginal Pain Associated With Sexual Activity, Symptoms Of Vulvar And Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral "Study Drug" 60 MG Daily Dose With Placebo In Postmenopausal Women

2008-Present: A Multi-Center, Placebo Controlled, Safety And Efficacy Study Of "Study Drug" In Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy

2008-Present: A Multicenter, Randomized, Double-Blind, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Doses Of "Study Drug" Versus Placebo In Women With Overactive Bladder

2007-2008: Long-Term Safety Of 30 MG And 60 MG Oral Daily Doses Of "Study Drug" In The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women With An Intact Uterus: A 40-Week Randomized, Double-Blind, Placebo-Controlled, Follow-Up To "Protocol"

2007-Present: A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Endometriosis

2007-Present: A Multi-Center, Randomized, Controlled Study To Investigate The Safety And Tolerability Of "Study Drug" vs. Standard Medical Care In Treating Iron Deficiency Anemia In Heavy Uterine Bleeding And Postpartum Patients

2007-2008: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation Of The Use Of Topically Administered "Study Drug" Versus Placebo In Subjects With Pain Associated With Fibrocystic Breast Disease

2007-Present: An Open Label Study Of The Contraceptive Efficacy Of An Extended Regimen Of "Study Drug" And "Study Drug"

2006-2008: A Randomized, Placebo-Controlled Phase II Study Of Multiple Dosing Regimens Of Intravaginally Administered "Study Drug" Gel For The Treatment Of Cervical High Risk HPV Infection

2006-2008: Efficacy And Safety Of "Study Drug" In The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral "Study Drug" 30 mg And 60 mg Daily Doses With Placebo


1-29-09